Announcements Trials
Browse Landscape

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Colorectal Neoplasms 3Sarcoma 2Colorectal Neoplasms, Hereditary Nonpolyposis 2Stage IIIb and IV Non Small Cell Lung Cancer 1Recurrence 1Prostatic Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Microsatellite Instability 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrence × High-Throughput Nucleotide Sequencing × Clear all
NCT05483257 2022-08-02

Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma

Ruijin Hospital

Completed
226 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡